Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1A | Q16819 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010216 | 0.86 | MEP1A (0.50) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL320434 | 0.85 | MEP1A (0.49) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL1009190 | 0.84 | NSD2 (0.42) | MAOBABCB1CHRM2CHRM1CHRM3 | |
| SCHEMBL2774213 | 0.81 | MEP1A (0.48) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL407544 | 0.79 | PTGES (0.44) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL2773661 | 0.79 | PTGES (0.44) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL16109388 | 0.76 | ERCC1 (0.46) | MEP1AMEP1BFFAR1FFAR4MAOB | |
| SCHEMBL408688 | 0.76 | MEP1A (0.45) | MEP1AMEP1BPTGESFFAR1FFAR4 | |
| SCHEMBL1008388 | 0.75 | PDK1 (0.38) | FFAR1FFAR4PDK1 | |
| SCHEMBL25182974 | 0.74 | FOLH1 (0.49) | MEP1AMEP1BPTGESFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2194058-B1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7119200-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | MEP1A 3156/4885MEP1B 3688/4885PTGES 1687/4885 |
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MEP1A 3499/4885MEP1B 3856/4885PTGES 1669/4885 |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MEP1A 3499/4885MEP1B 3856/4885PTGES 1669/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | MEP1A 2577/4885MEP1B 2864/4885PTGES 1335/4885 |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDK5 | MEP1A 3342/4885MEP1B 3758/4885PTGES 1848/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MEP1A 3499/4885MEP1B 3856/4885PTGES 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.